Novo Nordisk (NVO) said Tuesday it has filed for European Medicines Agency approval of a new, higher dose of its obesity treatment Wegovy, or semaglutide.
The application is supported by clinical trial data showing that treatment with the higher 7.2 mg subcutaneous dose led to an average 21% reduction in body weight among people with obesity with or without type 2 diabetes, with one in three patients achieving 25% or more weight loss, Novo Nordisk said.
The higher dose had a safety profile consistent with the currently approved 2.4 mg dose, the company added.
Price: 69.36, Change: +0.04, Percent Change: +0.06
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.